Codivir - Code Pharma
Latest Information Update: 28 Apr 2024
At a glance
- Originator Hebrew University of Jerusalem
- Developer Code Pharma
- Class Antineoplastics; Antivirals; Peptides
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered COVID 2019 infections
- Phase I HIV infections; Influenza virus infections
- Clinical Phase Unknown Cancer
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in COVID-2019-infections in Brazil (SC, Injection)
- 16 Mar 2022 Clinical trials in Cancer (SC), prior to March 2022 (Code Pharma pipeline, March 2022)
- 16 Mar 2022 Phase-I clinical trials in HIV infections in Netherlands (SC), prior to March 2022 (Code Pharma pipeline, March 2022)